Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 3, 1997, Pages 189-201

  Martin, Janet ^a   Stribbling, Stephen M ^a   Poon, Grace K ^a   Begent, Richard H J ^b   Napier, Mark ^b   Sharma, Surinder K ^b   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

ADEPT; Carboxypeptidase G2; Prodrug

Indexed keywords

ALKYLATING AGENT; CARBOXYPEPTIDASE G2; CJS 11; CYTOTOXIC AGENT; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG BLOOD LEVEL; DRUG DECOMPOSITION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030971014     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050646     Document Type: Article

References (22)

1. Antoniw P, Springer CJ, Bagshawe KD, Searle F, Melton RG, Rogers GT, Burke PJ, Sherwood RF (1990) Disposition of the prodrug 4-(bis (2-chloroethyl)-amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br J Cancer 62: 909
2. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF (1988) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700
3. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA, Rogers GT, Burke PJ, Melton RG, Sherwood RF (1991) Antibody directed enzyme prodrug therapy (ADEPT): clinical report. Dis Markers 9: 233
4. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Rogers GT, Burke PJ, Melton RG, Sherwood RF (1991) Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody Immunoconjugates Radiopharmaceuticals 4: 915
5. Bagshawe KD, Sharma SK, Springer CJ, Antoniw P (1995) Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting 1: 17
6. Baxter LT, Jain RK (1996) Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer 73: 447
7. Dowell R, Springer CJ, Davies DH, Hadley EM, Burke PJ, Boyle FT, Melton RG, Connors TA, Blakey DC, Mauger AB (1996) New mustard prodrugs for antibody directed enzyme prodrug therapy (ADEPT). J Med Chem 39: 1100
8. Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial fluid. Cancer Res 48: 7022
9. Mann J, Haase-Held M, Springer CJ, Bagshawe KD (1990) Synthesis of an N-mustard prodrug. Tetrahedron 46: 5377
10. Melton RG, Boyle JMB, Rogers GT, Burke PJ, Bagshawe KD, Sherwood RF (1993) Optimization of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J Immunol Methods 158: 49
11. Niculescu-Duvaz I, Springer CJ (1995) Antibody-directed enzyme prodrug therapy (ADEPT): a targeting strategy in cancer chemotherapy. Curr Med Chem 2: 687
12. Senter PD, Wallace PM, Svensson HP, Vrudhula VM, Kerr DE, Hellstrom I, Hellstrom KE (1993) Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem 4: 3
13. Sharma SK, Bagshawe KD, Burke PJ, Boden RW, Rogers GT (1990) Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Br J Cancer 61: 659
14. Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, Melton RG, Sherwood RF (1994) Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer 73: 1114
15. Springer CJ (1993) CMDA. Drugs Future 18: 212
16. Springer CJ, Antoniw P, Bagshawe KD, Searle F, Bissett GMF, Jarman M (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem 33: 677
17. Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF, Melton RG (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur J Cancer 27: 1361
18. Springer CJ, Antoniw P, Bagshawe KD, Wilman DEV (1991) Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des 6: 467
19. Springer CJ, Poon GK, Sharma SK, Bagshawe KD (1993) Identification of prodrug. active drug, and metabolites in an ADEPT clinical study. Cell Biophys 22: 9
20. Springer CJ, Poon GK, Sharma SK, Bagshawe KD (1994) Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study. Cell Biophys 24/25: 193
21. Springer CJ, Niculescu-Duvaz I, Pedley RB (1994) Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J Med Chem 37: 2361
22. Springer CJ, Dowell R, Burke PJ, Hadley E, Davies DH, Blakey DC, Melton RG, Niculescu-Duvaz I (1995) Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 38: 5051